GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.